Photo of Andrew N. WeberPhoto of Andrew N. Weber

Andrew N. Weber

Partner

Education

Michigan State University College of Law, J.D.
  • Jurisprudence Award in Advanced Criminal Procedure
  • Moot Court, Board Member, 2002-2003; Inns of the American Court, 2002-2003
University of Chicago, M.S.
  • Physical and Synthetic Organic Chemistry
Eastern Michigan University, B.S.
  • Chemistry

Prior Employment

  • Miller, Canfield, Paddock and Stone, P.L.C.
  • Warner Lambert (now Pfizer, Inc)
  • Aastrom Biosciences, Inc.
  • Dow Chemical Company

Bar Admissions

Court Admissions

Professional Affiliations

State Bar of Michigan

American Intellectual Property Law Association

American Bar Association

  • Intellectual Property Section

Materials Research Society

Overview
Experience
News & Resources
Honors

Overview

Mr. Weber counsels clients on a wide range of intellectual property matters dealing with patents, trademarks, trade secrets, copyrights, licensing of intellectual property, intellectual property litigation, and chemical technologies, including electrochemistry, nanotechnology, material science, agricultural science, and pharmaceuticals.

  • Assists clients in developing and implementing patent life cycle management strategies, conducting IP due diligence, negotiating and drafting patent license agreements, rendering legal opinions on patent validity and non-infringement
  • Drafts and prosecutes patent applications in a variety of technical areas such as electrochemistry, inorganic and polymer chemistries, material science, nanotechnology, pharmaceuticals, and mechanical engineering
  • Assists clients in managing worldwide prosecution of patent applications
  • Represents clients in energy, environmental, pharmaceutical, agricultural, medical device, and automotive industries as well as academic institutions
  • Manages and conducts due diligence reviews in M&A transactions for companies investing in battery technologies
  • Counsels small and medium-sized battery companies looking for capital investment
  • Advises university spin-offs in the battery field

Experience

  • Represented battery companies developing rechargeable battery systems
  • Represented a pharmaceutical start-up companies developing small molecule and biologic pharmaceuticals
  • Advised a multinational pharmaceutical company in developing a global patent strategy for a Phase II drug candidate, which involved obtaining patent issuances on the drug substance and implementing a patent life cycle management plan
  • Drafted and negotiated a variety of agreements: patent license, co-development and commercialization, material transfer, and non-disclosure agreements; and clinical trial agreements
  • Conducted intellectual property due diligence for venture fund clients regarding potential investments; large pharmaceutical and biotechnology corporations regarding potential asset purchases and mergers; and start-up companies regarding potential licensing of university or third party owned technologies
  • Obtained numerous U.S. Patents, including:
    • U.S. Patent No. 8,802,304: Bifunctional (rechargeable) air electrodes comprising a corrosion-resistant outer layer and conductive inner layer
    • U.S. Patent No. D586,739: Battery housing
    • U.S. Patent No. D586,738: Battery housing
    • U.S. Patent No. 7,488,558: Homogeneous separator
    • U.S. Patent No. 8,278,297: Protein kinase inhibitors
    • U.S. Patent No. 8,277,783: Permanganate containing whitening compositions and methods of their use
    • U.S. Patent No. 8,252,787: Protein kinase inhibitors
    • U.S. Patent No. 8,247,421: 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors
    • U.S. Patent No. 8,188,281: Azaindoles useful as inhibitors of JAK and other protein kinases
    • U.S. Patent No. 8,163,917: Azaindoles useful as inhibitors of Janus kinases
    • U.S. Patent No. 8,129,387: Substituted 5,6-dihydroimidazo [1,5-F] pteridines useful as protein kinase inhibitors
    • U.S. Patent No. 8,067,450: Thiazolidinedione analogues for the treatment of metabolic diseases
    • U.S. Patent No. 7,767,816: Azaindoles useful as inhibitors of janus kinases
    • U.S. Patent No. 7,563,795: Phenyl-piperazine derivatives as modulators of muscarinic receptors
    • U.S. Patent No. 7,446,112: Modulators of muscarinic receptors

News & Resources

Publications

Seminars & Events

Honors

  • Michigan Super Lawyers, Recognized as a Rising Star, 2013-2015